Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that ...

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...

A $5,000 investment can go a long way, especially if you're loading up on fairly cheap stocks that may possess a lot of ...

In a judgment of 23 December 2024, the Dutch-speaking Enterprise Court of Brussels followed the reasoning of a Dutch court earlier in 2024, ...

Analysts have previously suggested that Lumakras could become a $1 billion-plus product if Amgen can extend the label for the drug into the first-line NSCLC setting and also get approval for the ...

Defense tech company Anduril is investing nearly $1 billion and plans to create 4,000 jobs in Ohio. How does that compare to ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute myocardial infarction (AMI) and unstable angina, an aging global population ...

The global placental growth factors market is poised for remarkable growth, with projections indicating a surge from USD 34.9 ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...